Pinned Tweet
Oncology education in LMICs is changing — and the group chat is not just a group chat anymore. In our @JCOGO_ASCO paper, we surveyed 202 oncology professionals across 13 countries. Key signals:
📌 61% used X/Twitter as their primary oncology information source. 1/8
What a wonderful time i had with Dr El-Deiry. Thank you for the warm hospitality!
I said good bye to Dr. Karan Sood at Logan Airport this afternoon as he heads back to Mumbai, India. The time he spent with us at @BrownUniversity and @BrownUnivHealth as a @WINConsortium Precision Oncology Fellow was productive and sets the stage for future work and collaboration. @Dr_R_Kurzrock @SewantiLimaye @LiaTsimberidou @VivekSubbiah @DrChoueiri @TataMemorial
Dr. Karan Sood retweeted
I said good bye to Dr. Karan Sood at Logan Airport this afternoon as he heads back to Mumbai, India. The time he spent with us at @BrownUniversity and @BrownUnivHealth as a @WINConsortium Precision Oncology Fellow was productive and sets the stage for future work and collaboration. @Dr_R_Kurzrock @SewantiLimaye @LiaTsimberidou @VivekSubbiah @DrChoueiri @TataMemorial
Dr. Karan Sood retweeted
What Started as an Opportunity to Contribute Has Become a Lesson in Leadership - Karan Sood (@QuantumOnc)
oncodaily.com/voices/karan-s…
Dr. Karan Sood retweeted
As a @ManUtd fan, I think @ManCity should be relegated and not allowed to play in the URFA this year.
What say you? @scserendipity1 @Dr_AmerZeidan @keith_giles @ASkarbnik
theguardian.com/football/202…
Dr. Karan Sood retweeted
A Multidisciplinary Framework for the Management of Periampullary Adenocarcinomas in Indian Oncology Practice - Karan Sood (@QuantumOnc)
oncodaily.com/voices/karan-s…
Dr. Karan Sood retweeted
Honoured to receive the ISMPO-Shri Vijay Batra Research Foundation Award 2026 for Best Original Manuscript (METRO PLUS) — Integrating Metronomic Therapy in Unresectable Head & Neck Cancer.
Grateful to ISMPO,mentors & patients.
Full text: ascopubs.org/doi/full/10.120… @TMC_Varanasi
Dr. Karan Sood retweeted
Rare Cancers Are Rare Individually, but Their Collective Challenge Is Anything but Rare - Karan Sood
@QuantumOnc
oncodaily.com/voices/karan-s…
Dr. Karan Sood retweeted
Replying to @skchettry
I completely agree with you. Senior doctors have promoted two very awful matters - one is the publish or perish in academics and the second is "seeing more patients or working like a horse" at the cost of quality of life. This is classical positive toxicity which must be stopped.
Dr. Karan Sood retweeted
Rapid fire discussion on #WCLC26 with global oncology colleagues Drs. @LauraAlderMD @TejasPatilMD @ChandrakanthMv @QuantumOnc @ullas_batra @g_mountzios led by @SuyogCancer - always appreciate the different perspectives everyone brings to the emerging data.
It was a wonderful discussion
A huge thank you to our incredible faculty @StephenVLiu @LauraAlderMD @TejasPatilMD @g_mountzios @ullas_batra Dr Chandrakanth, Dr Karan Sood for an outstanding #OncoWisdom discussion on What’s New in Lung Cancer from WCLC 2026. 🙏
402 registrations | 160 attendees
Grateful for the time, expertise and honest discussion 🙂.
Thank you for making it special! 🙏
And thank you for all those who attended it . I hope it was useful for all of you 🙂
Dr. Karan Sood retweeted
Karan Sood Selected for the ISMPO Principal Amritlal Mohanlal Parikh Best Emerging Teacher of the Year Award 2026
@QuantumOnc
oncodaily.com/voices/karan-s…
Dr. Karan Sood retweeted
🎉Another successful session of #IASCOMolecule Season 3! Our 12th session on "Drugs in Myeloid Neoplasm," with Dr Hari Menon as Examiner & Dr. Ramesh Balasubramanian as Speaker received an overwhelming response by participants. Thank you to everyone who had joined.
Dr. Karan Sood retweeted
I can’t believe this is my life!! 🥹
My favourite football club has featured me and my artwork on Instagram 😭❤️
Best club in the world for a reason! 🌎
#MUFC
Dr. Karan Sood retweeted
Absolutely in awe and admiration for @rachnatshroff, FASCO who is supporting the permanent endowment of a @ConquerCancerFd , @ASCO Foundation Young Investigator Award, while she fights cancer herself. All my love and support to you. Please donate: support.conquer.org/p2p/site…
Dr. Karan Sood retweeted
Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma.
Read more:
Dr. Karan Sood retweeted
Congrats to cholangiocarcinoma community, @OncoSil @curecc @UTMDAnderson @lisamariecraine for HDE approval by FDA in Distal CCa
cancernetwork.com/view/fda-g…
Dr. Karan Sood retweeted
Dear Colleagues,
We are conducting a global oncology survey on how routine AI use may influence memory, reasoning, verification of evidence, and clinical thinking in oncology practice. In this fast-paced academic world, is AI helping us think better or making us forget what we once knew?
Your response will help us understand this important issue. The survey is anonymous and takes only 5–7 minutes.
After 300 valid responses, there will be:
2 co-author opportunities for meaningful dissemination support, subject to ICMJE authorship criteria
Please complete and share with oncology colleagues:
forms.gle/7W58st8hN5pUiWoT7
Thank you.
Dr. Karan Sood retweeted
INSANE Nature paper
Dendritic cell erythropoietin receptor is tolerogenic...remove it and #cancer goes away
pmc.ncbi.nlm.nih.gov/article…
Dr. Karan Sood retweeted
Join us for the next MOLECULE – Chemotherapy Foundations Session Gastrointestinal Cancer where we dissect chemotherapy concepts with clinical reasoning.📆9th August 2 PM IST
#Molecule #OncologyFellows #IASCO #Chemotherapy #DM #DrNB #YoungOncologists #MedEd #GastrointestinalCancer
Dr. Karan Sood retweeted
Leveraging Social Media for Oncology Education and Practice: Perspective from Low and Middle Income Countries.
Read the full article. bit.ly/44dJG5m







































